Who Is The Best Minor League Player In The Drug Pricing Debate?
Executive Summary
Now that the Senate Finance Committee has unveiled its bill and House leadership has outlined its approach, less comprehensive drug pricing legislation is losing the limelight. But may of the the bills could still have a meaningful impact on pharma, and might even become law, if only because they would be an easier way for politicians to show they were doing something to address the issue.
You may also be interested in...
Drug Pricing Policies Attached To Surprise Medical Billing Legislation
Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.
California's Pay-For-Delay Law May Be Harsher Than FTC Regulation, Could Face Legal Challenge
Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.
Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance
Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.